A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

INTRODUCTION: JUNIPER compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, with erlotinib in patients with non-small cell lung cancer (NSCLC) harboring a Kirsten rat sarcoma (KRAS) mutation. METHODS: JUNIPER was a Phase III, multicenter, randomized,...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman, Jonathan W., Mazieres, Julien, Barlesi, Fabrice, Dragnev, Konstantin H., Koczywas, Marianna, Göskel, Tuncay, Cortot, Alexis B., Girard, Nicolas, Wesseler, Claas, Bischoff, Helge, Nadal, Ernest, Park, Keunchil, Lu, Shun, Taus, Alvaro, Cobo, Manuel, Estrem, Shawn T., Wijayawardana, Sameera R., Turner, Kellie, Oakley, Gerard Joseph, Hurt, Karla C., Chiang, Alan Y., Hossain, Anwar M., John, William J., Paz-Ares, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649422/
https://www.ncbi.nlm.nih.gov/pubmed/33194700
http://dx.doi.org/10.3389/fonc.2020.578756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649422/
https://www.ncbi.nlm.nih.gov/pubmed/33194700
http://dx.doi.org/10.3389/fonc.2020.578756

Ejemplares similares